NYSE-listed pharma major Abbott Labs has inked a deal with Piramal Healthcare to acquire Piramal’s Healthcare Solutions business. Abbott to Become No. 1 Pharmaceutical Company in India with Acquisition of Piramal’s Healthcare Solutions Business. May 21, am. N) will pay $ billion to acquire the branded generics business of Piramal’s healthcare solutions accounted for about 55 percent of its.

Author: Fenrizragore Yozshucage
Country: Botswana
Language: English (Spanish)
Genre: Politics
Published (Last): 23 March 2012
Pages: 186
PDF File Size: 15.20 Mb
ePub File Size: 19.78 Mb
ISBN: 574-1-68724-382-2
Downloads: 37197
Price: Free* [*Free Regsitration Required]
Uploader: Dairisar

It will, however, continue research in drug discovery through an affiliate company. All the cash from the deal will go into Piramal Healthcare and will be invested in existing business segments such as consumer healthcare or the Pirsmal unit, the critical care segment and drug research, chairman Piramal said. India’s rapid pharmaceutical market growth is being driven largely by branded generics.

Food and Drug Administration charged the Lf company with numerous violations on quality and safety fronts, and banned some of its drugs. Sbbott watch list my. The business will continue to be led by its current India-based management team. Login from existing account Facebook Google Email. To verify, just follow the link in the message. Abbott Piramal Healthcare pain neuroscience generics antibiotics.

It is not so much a concern about the downside, but about how we maximize the opportunity. According to Abbott, this deal further accelerates Abbott’s emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott’s collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Acquosition to focus on expanding the global markets for its leading branded generics portfolio.

For consumers, the great value in generics is getting it cheaper. Read Post a comment. Abbott announced it intends to close the acquisition of St.

A ‘Bigger Foothold’: What Does the Abbott-Piramal Deal Mean for Indian Pharma? – [email protected]

Ajay Piramal, however, reiterated that he was not exiting the business. Piramal’s Healthcare Solutions business employs over 5, people in India. Abbott, which will fund the transaction with cash on the balance sheet, says, the deal will be conducted through its wholly-owned subsidiary. Advertising Branding Clinical research Conferences meetings events Creative and design Digital communications Homecare Industry associations IT solutions Management consultancies Manufacturing packaging logistics Market access Market research Marketing consultancies Media planning and buying Medical communications Medical education Patient support and adherence Pharmacy Print services Policy and government affairs Public relations Publishers Recruitment and career development Regulatory affairs Research and development Sales Training Translation services Consulting at McCann Health We are the strategic consultancy of McCann Health.


Unnikrishnan and Satish John. The earlier regime recognized patents on pharmaceutical processes but not on pharmaceutical products, allowing companies to reverse-engineer copies of the branded and patented drugs of western companies.

My watch list My saved searches My saved piramzl My newsletter Register free of charge. Abbott will pay Rs per share. Sat, May 22 As Abbott wanted to make a significant presence in India, they feel it is reasonable.

Log in Keep me signed in. Share on Facebook Share on Twitter. The stock markets reacted negatively to the deal. Commenting on the acquisition, Miles D White, chairman and chief executive officer of Abbott stated that it further strengthened Abbott’s growing presence lf emerging markets.

The collaboration includes medicines for pain, cancer and cardiovascular, neurological and respiratory diseases, with product launches beginning in Your browser does not support JavaScript.

Abbott buys Piramal unit, tops table

Read what healthhcare need to know about our industry portal bionity. For MNCs, emerging markets, with their cheaper generic medicines, are turning out to be the new battleground, given that most are witnessing stalled sales in Western markets.

According healtchare Abbott statement, branded generics have significant brand equity in many international markets, providing durable, sustainable franchises for future growth.


These other players are not even interested in doing that. The hunter has become the hunted. Several other deals occurred over the past one year.

Abbott buys Piramal’s pharma arm for $bn – Times of India

More news by Abbott. Abbott Gesellschaft mbH more. With an accout for my. Refrain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks, name calling or inciting hatred against any community. Leave Your Comment s. Trending New bealthcare of care China Special: The Indian drug maker, which itself has made 15 acquisitions sinceinsists it will remain in the industry and invest in the remaining business.

Abbott and other Big Pharma companies face the twin challenges of slow growth in the developed markets and maturing product pipelines that are getting harder to replenish with newer, blockbuster drugs, according to Chaudhuri. In Germany, Abbott has approximately 2, heapthcare working in manufacturing, research and development, logistics, sales and marketing.

BOas global drugmakers look to boost their presence in emerging markets. According to Reuters, Abbott was advised by Morgan Stanley. At the same time, hopes have receded of a wholly Indian pharmaceutical major emerging as a global solutiojs. Piramal Enterprises enters into an agreement to wolutions Ash Stevens Inc.

According to Wharton faculty and industry experts, changing global business models and the resources needed to develop blockbuster drugs are propelling Indian companies to join forces with multinationals through strategic alliances or as targets for acquisitions. Request information now On my watchlist.

It will continue its drug discovery and research through Piramal Life Sciences Ltd. The Thomson Reuters Trust Principles.